PML/RARA Fusion Probe

PML/RARA Fusion Probe

Product Description:Acute myeloid leukemia/AML(Non APL)
Applications: Lymphatic hematopoietic system tumor

Send InquiryChat Now
Product Details

1

PML/RARA fusion probe

图像_42112图像_49522
                          PML/RARA(+)                                 PML/RARA(-)



Product Advantages

1.Fleetness: Tissue probe hybridization time: 2 hours. Cell probe hybridization time: 1 hour. 

2.Accuracy: Less non-specific background staining (dyeing). Increase difficult samples detection rate.

3.Reproducibility: Different laboratories test results are highly reproducible.


◆Probe Description

image002.jpg

PML/RARA gene fusion probe  uses the PML probe labeled with orange red dye and the RARA probe labeled with green dye, the two probes can be combined with the target detection site by in situ hybridization. Normally (PML / RARA gene did not fuse), two orange and two green signals were displayed under fluorescence microscopy. When fusion genes exist, green and orange signals are reconstituted to form yellow fusion signals.


◆Clinical Significance

PML/RARA fusion gene is a characteristic marker of acute promyelocytic leukemia (APL). PML / RARA fusion proteins inhibit the differentiation and maturation of promyelocytes through dominant negative inhibition, thereby blocking cell differentiation and leading to sustained proliferation. All trans retinoic acid (ATRA) and arsenic trioxide can degrade PML/RARA fusion protein, restore the function of wild type PML and RARA gene, relieve the inhibition of gene transcription, induce cell differentiation and apoptosis, so that APL can be effectively treated. The combined use of ATRA and chemotherapy can achieve a complete remission rate of APL for 90%~95%, More than 70% of the patients can survive for a long time.


◆Size Specifications

image006.jpg


Hot Tags: PML/RARA fusion probe, suppliers, manufacturers, customized, discount, IVD, free sample, for laboratories, for hospitals, for research center, rapid diagnosis
Related Products
Inquiry